Skip to main content

Animations

MJFF Publications

1701 - 1725 of 8479 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • Summary Details
    OPEN
    Title: Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy
    Journal Name: International Journal of Molecular Sciences
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/ijms232314554
    Citation Count: 7
  • Summary Details
    RESTRICTED
    Title: Spillover: The Approval of New Medications for Alzheimer’s Disease Dementia Will Impact Biomarker Disclosure Among Asymptomatic Research Participants
    Journal Name: Journal of Alzheimer's Disease
    Publisher: IOS Press
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.3233/jad-220113
    Citation Count: 3
  • Summary Details
    OPEN
    Title: The Effects of Deep Brain Stimulation in Patients with Multiple System Atrophy
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.3233/jpd-223504
    Citation Count: 8
  • Summary Details
    RESTRICTED
    Title: Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis
    Journal Name: CNS Drugs
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1007/s40263-022-00963-9
    Citation Count: 14
  • Summary Details
    OPEN
    Title: Screening performances of an 8-item UPSIT Italian version in the diagnosis of Parkinson’s disease
    Journal Name: Neurological Sciences
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s10072-022-06457-2
    Citation Count: 6
  • Summary Details
    OPEN
    Title: Human pericytes degrade diverse α-synuclein aggregates
    Journal Name: PLOS ONE
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1371/journal.pone.0277658
    Citation Count: 11
  • Summary Details
    RESTRICTED
    Title: Isolation of Human Microglia from Neuropathologically Diagnosed Cases in the Single-Cell Era
    Journal Name: Methods in Molecular Biology
    Publisher: Springer US
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/978-1-0716-2655-9_3
    Best OA location URL:
    Citation Count: 2
  • Summary Details
    OPEN
    Title: LUBAC assembles a ubiquitin signaling platform at mitochondria for signal amplification and transport of NF‐κB to the nucleus
    Journal Name: The EMBO Journal
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.15252/embj.2022112006
    Citation Count: 25
  • Summary Details
    RESTRICTED
    Title: Somatic CNV Detection by Single-Cell Whole-Genome Sequencing in Postmortem Human Brain
    Journal Name: Methods in Molecular Biology
    Publisher: Springer US
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/978-1-0716-2655-9_11
    Best OA location URL:
    Citation Count: 3
  • Summary Details
    RESTRICTED
    Title: Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy
    Journal Name: International Journal of Molecular Sciences
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/ijms232214340
    Citation Count: 8
  • Summary Details
    OPEN
    Title: BDNF rs10501087, rs1491850 and rs11030094 polymorphisms associated with delayed progression in early-stage Parkinson's disease
    Journal Name: Frontiers in Neurology
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fneur.2022.1053591
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome
    Journal Name: Alzheimer's Research & Therapy
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13195-022-01113-5
    Citation Count: 111
  • Summary Details
    OPEN
    Title: Subjective cognitive complaints are important in PD-MCI criteria: Associations with CSF markers and cognitive decline
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.11.013
    Citation Count: 4
  • Summary Details
    RESTRICTED
    Title: Major advances in Parkinson's disease over the past two decades and future research directions
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3
    Best OA location URL:
    Citation Count: 13
  • Summary Details
    RESTRICTED
    Title: Revisiting levodopa for advanced Parkinson's disease
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00435-5
    Best OA location URL:
    Citation Count: 1
  • Summary Details
    RESTRICTED
    Title: Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00400-8
    Best OA location URL:
    Citation Count: 98
  • Summary Details
    OPEN
    Title: Universal clinical Parkinson’s disease axes identify a major influence of neuroinflammation
    Journal Name: Genome Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1186/s13073-022-01132-9
    Citation Count: 9
  • Summary Details
    RESTRICTED
    Title: Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease
    Journal Name: CNS Drugs
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s40263-022-00973-7
    Best OA location URL:
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-022-34667-x
    Citation Count: 201
  • Summary Details
    OPEN
    Title: Altered Cortical Palmitoylation Induces Widespread Molecular Disturbances in Parkinson’s Disease
    Journal Name: International Journal of Molecular Sciences
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/ijms232214018
    Citation Count: 16
  • Summary Details
    RESTRICTED
    Title: Genotype–Phenotype Correlations for ATX‐TBP (SCA17): MDSGene Systematic Review
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.29278
    Citation Count: 7
  • Summary Details
    OPEN
    Title: Movement Disorders andSARS‐CoV‐2
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mdc3.13615
    Citation Count: 3
  • Summary Details
    OPEN
    Title: APOE E4 is associated with impaired self-declared cognition but not disease risk or age of onset in Nigerians with Parkinson’s disease
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-022-00411-x
    Citation Count: 9
  • Summary Details
    OPEN
    Title: Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson’s Disease
    Journal Name: International Journal of Molecular Sciences
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/ijms232213985
    Citation Count: 10
  • Summary Details
    OPEN
    Title: Biomarkers and non-motor symptoms as a function of motor symptom asymmetry in early Parkinson's disease
    Journal Name: Neuropsychologia
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuropsychologia.2022.108419
    Citation Count: 10
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.